Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bral, Jackie
NCT05399368: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis	Terminated	2	229	Canada, US	RPT193, Placebo	RAPT Therapeutics, Inc.	Atopic Dermatitis	05/24	05/24
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Active, not recruiting	2	72	Europe, Canada, US, RoW	Placebo/Daxdilimab, Daxdilimab, HZN-7734	Amgen, Horizon Therapeutics Ireland DAC	Discoid Lupus Erythematosus	09/25	09/25